Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

Summary

This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.

Timeline

Start

2006-02-21

Primary completion

2007-08

Completion

2007-09-24

Outcome

Met primary endpoint

paper Serlopitant (0.25 and 4 mg) significantly decreased the primary end point of daily micturitions but not the secondary end points compared with placebo. PMID 20639026 ↗

Publications

• Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147. Epub 2010 Jun 19.

Drugs

Indications